keyword
MENU ▼
Read by QxMD icon Read
search

RECIST

keyword
https://www.readbyqxmd.com/read/29161241/determination-of-an-optimal-response-cut-off-able-to-predict-progression-free-survival-in-patients-with-well-differentiated-advanced-pancreatic-neuroendocrine-tumours-treated-with-sunitinib-an-alternative-to-the-current-recist-defined-response
#1
Angela Lamarca, Jorge Barriuso, Matthew Kulke, Ivan Borbath, Heinz-Josef Lenz, Jean Luc Raoul, Neal J Meropol, Catherine Lombard-Bohas, James Posey, Sandrine Faivre, Eric Raymond, Juan W Valle
BACKGROUND: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size decrease from baseline) are infrequent. METHODS: Individual data of pNET patients from the phase II [NCT00056693] and pivotal phase III [NCT00428597] trials of sunitinib were analysed in this investigator-initiated, post hoc study...
November 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29158911/a-retrospective-evaluation-of-activity-of-gemcitabine-platinum-regimens-in-the-treatment-of-recurrent-ovarian-cancer
#2
Tran N Le, Rachel E Harvey, Christine K Kim, Jubilee Brown, Robert L Coleman, Judith A Smith
Background: While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/carboplatin and gemcitabine/cisplatin have a similar ORR in separate clinical trials, the tworegimens have never been directly been compared. With overlapping dose-limiting toxicity of thrombocytopenia, the gemcitabine/carboplatin regimen has been challenging to employ in the clinical setting in previously treated ovarian cancer patients and is often associated with treatment delays and/or dose reductions...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/29155512/efficacy-and-safety-of-cetuximab-plus-folfox-in-second-line-and-third-line-therapy-in-metastatic-colorectal-cancer
#3
Ersin Ozaslan, Ulas Serkan Topaloglu, Mevlude Inanc, Umut Gokmen Erdem, Hacer Demir, Erkan Arpaci, Mehmet Metin Seker, Mustafa Karaagac, Melih Kiziltepe, Baki Eker, Metin Ozkan
PURPOSE: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. METHODS: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were alsï given irinïtecan and/ïr ïxaliplatin cïmbined with fluorïpyrimidine±bevacizumab. Tumor respïnse and survival were evaluated using RECIST and Kaplan-Meier methïd respectively...
July 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29151955/continuation-of-tyrosine-kinase-inhibitor-is-associated-with-survival-benefit-in-nsclc-patients-with-exon-19-deletion-after-solitary-progression
#4
Feifei Na, Jie Zhang, Lei Deng, Xiaojuan Zhou, Lin Zhou, Bingwen Zou, Min Yu, Yanying Li, Jianxin Xue, Yongmei Liu
INTRODUCTION: The benefit and selection criteria of continuing tyrosine kinase inhibitor (TKI) after secondary resistance in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutation remain largely unknown. This study was designed to investigate the role and predictive factors of TKI continuation in patients with solitary progression. METHODS: We retrospectively analyzed NSCLCs treated with first generation of TKI from June 2009 to October 2014 in our cancer center...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29151293/-clinical-analysis-of-36-cases-of-advanced-non-small-cell-lung-cancer-nsclc-with-performance-status-ps-scores-between-2-and-4
#5
Y Y Qin, D H Zhang, X Q Lin, M Ouyang, J X Zhang, Z H Xie, Y Q Liu, S Y Li, C Z Zhou
Objective: To analyze the treatment of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4, in order to improve the diagnosis and treatment of these patients. Methods: A total of 36 patients with advanced NSCLC with hypoxemia were reviewed. The clinical data of disease characteristics, etiology, complications, manifestation, therapy, progression, and secondary biopsy were collected. The clinical efficacy was graded according to the Response Evaluation Criteria In Solid Tumors (RECIST): complete response (CR), partial response (PR), stable disease (SD) and disease progression (PD)...
November 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/29150792/correlation-between-mgmt-promoter-methylation-and-response-to-temozolomide-based-therapy-in-neuroendocrine-neoplasms-an-observational-retrospective-multicenter-study
#6
Davide Campana, Thomas Walter, Sara Pusceddu, Fabio Gelsomino, Emmanuelle Graillot, Natalie Prinzi, Andrea Spallanzani, Michelangelo Fiorentino, Marc Barritault, Filippo Dall'Olio, Nicole Brighi, Guido Biasco
PURPOSE: Temozolomide (TEM) based therapy has been reported being effective in the treatment of metastatic neuroendocrine neoplasms (NEN), with response rates ranging from 30 to 70%. Among patients affected by advanced glioblastoma or melanoma and treated with TEM, loss of tumoral O6-methylguanine DNA methyltransferase (MGMT) is correlated with improved survival. In NEN patients, the role of MGMT deficiency in predicting clinical outcomes of TEM treatment is still under debate. METHODS: In this study we evaluated 95 patients with advanced NENs undergoing treatment with TEM-based therapy...
November 17, 2017: Endocrine
https://www.readbyqxmd.com/read/29138343/a-phase-i-clinical-trial-of-the-poly-adp-ribose-polymerase-inhibitor-veliparib-and-weekly-topotecan-in-patients-with-solid-tumors
#7
Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, Harry J Long, Donald W Northfelt, Joel M Reid, Felix Boakye-Agyeman, Olumide Kayode, Karen S Flatten, Maria I Harrell, Elizabeth M Swisher, Guy G Poirer, Daniel Satele, Jacob B Allred, Janet L Lensing, Alice Chen, Jiuping Jay Ji, Yiping Zhang, Charles Erlichman, Paul Haluska, Scott H Kaufmann
PURPOSE: To determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of veliparib in combination with weekly topotecan in patients with solid tumors. Correlative studies were included to assess the impact of topotecan and veliparib on poly(ADP-ribose) levels in peripheral blood mononuclear cells, serum pharmacokinetics of both agents, and potential association of germline repair gene mutations with outcome. EXPERIMENTAL DESIGN: Eligible patients had metastatic nonhematological malignancies with measurable disease...
November 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29133316/study-protocol-for-think-a-multinational-open-label-phase-i-study-to-assess-the-safety-and-clinical-activity-of-multiple-administrations-of-nkr-2-in-patients-with-different-metastatic-tumour-types
#8
Caroline Lonez, Bikash Verma, Alain Hendlisz, Philippe Aftimos, Ahmad Awada, Eric Van Den Neste, Gaetan Catala, Jean-Pascal H Machiels, Fanny Piette, Jason B Brayer, David A Sallman, Tessa Kerre, Kunle Odunsi, Marco L Davila, David E Gilham, Frédéric F Lehmann
INTRODUCTION: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3ζ signalling domain, which associates with the adaptor molecule DNAX-activating protein of 10 kDa (DAP10) to provide co-stimulatory signal upon ligand binding. NKG2D binds eight different ligands expressed on the cell surface of many tumour cells and which are normally absent on non-neoplastic cells...
November 12, 2017: BMJ Open
https://www.readbyqxmd.com/read/29129441/health-related-quality-of-life-results-for-pembrolizumab-versus-chemotherapy-in-advanced-pd-l1-positive-nsclc-keynote-024-a-multicentre-international-randomised-open-label-phase-3-trial
#9
Julie R Brahmer, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Jin Zhang, Gregory M Lubiniecki, Anne C Deitz, Reshma Rangwala, Martin Reck
BACKGROUND: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cell death-ligand 1 (PD-L1) tumour proportion score of 50% or greater (PD-L1-positive). Here we report the prespecified exploratory endpoint of pembrolizumab versus chemotherapy on patient-reported outcomes (PROs). METHODS: In this multicentre, international, randomised, open-label, phase 3 trial, we recruited patients with treatment-naive, stage IV NSCLC in 102 sites in 16 countries...
November 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29124987/outcomes-of-treatment-with-sorafenib-in-egyptian-patients-with-hepatocellular-carcinoma-a-retrospective-cohort-study
#10
Yousery Nada, Noha Rashad, Mai Eissa, Aya Ghonaim, Kyrillus Farag, Islam Saadawi, Ahmed Sheha, Mahmoud El Gewaity, Omar Abdel-Rahman
BACKGROUND: Sorafenib is the standard of care, first line treatment for advanced HCC. This study aims to evaluate real-life efficacy and safety of sorafenib in Egyptian patients with Hepatocellular carcinoma (HCC). RESEARCH DESIGN AND METHODS: This retrospective cohort study was conducted in the medical oncology department at Maadi Armed Forces Medical Compound. Patients with advanced HCC who received sorafenib between January and December 2015 were included (130 patients)...
November 10, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29124456/serial-immunological-parameters-in-a-phase-ii-trial-of-exemestane-and-low-dose-oral-cyclophosphamide-in-advanced-hormone-receptor-positive-breast-cancer
#11
Maryann Kwa, Xiaochun Li, Yelena Novik, Ruth Oratz, Komal Jhaveri, Jennifer Wu, Ping Gu, Marleen Meyers, Franco Muggia, James Speyer, Alyssa Iwano, Maryam Bonakdar, Lina Kozhaya, Ece Tavukcuoglu, Bahar Budan, Roy Raad, Judith D Goldberg, Derya Unutmaz, Sylvia Adams
BACKGROUND AND PURPOSE: Resistance to endocrine therapies in hormone receptor (HR)-positive breast cancer is a significant challenge. Prior studies have shown that low-dose oral cyclophosphamide can transiently deplete regulatory T cells (Tregs) and improve anti-tumor immunity. We investigated the combination of exemestane with cyclophosphamide in patients with advanced HR-positive breast cancer and assessed changes in circulating immune cell subsets. METHODS: This was a single-arm phase II trial of exemestane with cyclophosphamide in patients with metastatic HR-positive/HER2-negative breast cancer who had progressed on prior endocrine therapy (ClinicalTrials...
November 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29119276/phase-ib-ii-study-of-gemcitabine-nab-paclitaxel-and-pembrolizumab-in-metastatic-pancreatic-adenocarcinoma
#12
Glen J Weiss, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Howard Urnovitz, Ekkhard Schütz, Vivek Khemka
Background A single center phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab (GNP) to evaluate the safety and efficacy in metastatic pancreatic adenocarcinoma (PDAC) was conducted (NCT02331251). Methods PDAC patients (pts) with measurable disease, biopsy proven metastasis, adequate laboratory tests, and KPS ≥ 70% received GNP until progression or toxicity. Safety monitoring, RECIST 1.1, and irRECIST assessments were conducted. Response imaging was performed prior to cycle 4, then every 3 months...
November 8, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29116489/long-term-survival-according-to-histology-and-radiologic-response-to-preoperative-chemotherapy-in-126-patients-undergoing-resection-of-non-gist-sarcoma-liver-metastases
#13
Claire Goumard, Leonardo P Marcal, Wei-Lien Wang, Neeta Somaiah, Masayuki Okuno, Christina L Roland, Ching-Wei D Tzeng, Yun Shin Chun, Barry W Feig, Jean-Nicolas Vauthey, Claudius Conrad
BACKGROUND: Non-gastrointestinal stromal tumor sarcomas (NGSs) have heterogeneous histology, and this heterogeneity may lead to uncertainty regarding the prognosis of patients with liver metastases from NGS (NGSLM) and decision regarding their surgical management. Furthermore, the role of preoperative chemotherapy in treatment of NGSLM remains poorly defined. We investigated long-term survival and its correlation to response to preoperative chemotherapy in patients with NGSLM. PATIENTS AND METHOD: Patients who underwent liver resection for NGSLM during 1998-2015 were identified...
November 7, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29116100/the-value-of-cbct-based-tumor-density-and-volume-variations-in-prediction-of-early-response-to-chemoradiation-therapy-in-advanced-nsclc
#14
Qiang Wen, Jian Zhu, Xue Meng, Changsheng Ma, Tong Bai, Xindong Sun, Jinming Yu
The correlations between early responses and the variations in physical density and primary tumor volume (TV) according to cone-beam computed tomography (CBCT) during chemoradiotherapy for non-small cell lung cancer (NSCLC) patients were investigated. 54 patients with inoperable and locally advanced NSCLC were included in this study. The CT numbers (CTN) and TV were measured on each of the seven observation points. The changes in the mean CTN values and the variation ratios of TV during the treatment course were analysed and correlated with the clinical outcomes, as evaluated by the RECIST criteria...
November 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29113950/reviewing-recist-in-the-era-of-prolonged-and-targeted-therapy
#15
REVIEW
Rustain L Morgan, D Ross Camidge
Accurate assessment of disease response is the foundation of therapeutic trails, which is why the Response Evaluation Criteria in Solid Tumors (RECIST) criteria serves as an international standard investigators can utilize when examining patient outcomes. Nine years after the initial RECIST criteria were released, an update, RECIST 1.1, was published to improve on initial criteria and address technologic advancements in imaging. Since then advancements in both standard clinical and trial practices, combined with improvements in our understanding of cancer biology have resulted in the identification of a number of limitations of the current RECIST 1...
November 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29113660/functional-hepatic-imaging-as-a-biomarker-of-primary-and-secondary-tumor-response-to-loco-regional-therapies
#16
REVIEW
H L Lewis, M A Ghasabeh, P Khoshpouri, I R Kamel, T M Pawlik
Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29113403/a-phase-2-open-label-multi-center-study-of-amuvatinib-in-combination-with-platinum-etoposide-chemotherapy-in-platinum-refractory-small-cell-lung-cancer-patients
#17
Lauren Averett Byers, Leora Horn, Jitendra Ghandi, Goetz Kloecker, Taofeek Owonikoko, Saiama Naheed Waqar, Maciej Krzakowski, Robert J Cardnell, Junya Fujimoto, Pietro Taverna, Mohammad Azab, David Ross Camidge
Background: Amuvatinib (MP-470) is a multi-targeted kinase inhibitor with potent activity against c-Kit, synergistic with DNA-damaging agents. We evaluated amuvatinib in combination with platinum-etoposide (EP) chemotherapy by objective response rate, survival, and tolerability in platinum-refractory small cell lung cancer (SCLC) patients. Methods: This study used a Simon 2-stage design requiring ≥3 centrally confirmed responses in the first 21 subjects. Subjects received EP with 300 mg amuvatinib orally three times daily in cycles of 21 days...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29110655/treatment-of-gastrointestinal-stromal-tumours-in-paediatric-and-young-adult-patients-with-sunitinib-a-multicentre-case-series
#18
Piotr Rutkowski, Heather Magnan, Alexander J Chou, Charlotte Benson
BACKGROUND: Gastrointestinal stromal tumours (GIST) are rarely encountered mesenchymal tumours of the gastrointestinal tract (1.5 people per 100,000/year) that are even more rarely seen in paediatric patients (1-2% of all cases). The standard treatment for advanced adult GIST is imatinib with sunitinib as a second-line option. Although the efficacy and tolerability of sunitinib in adults with GIST has been established, little is known of the profile of sunitinib in paediatric/young adult patients with GIST given the rarity of this disease...
November 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29108254/the-impacts-of-genetic-polymorphisms-in-genes-of-base-excision-repair-pathway-on-the-efficacy-and-acute-toxicities-of-chemo-radiotherapy-in-patients-with-nasopharyngeal-carcinoma
#19
Jing Wang, Chengxian Guo, Xiaochang Gong, Fan Ao, Yuling Huang, Lihua Huang, Yiqiang Tang, Chunling Jiang, Xiaoxue Xie, Qing Dong, Min Huang, Jingao Li
Purpose: To explore whether polymorphisms in base excision repair (BER) pathway genes are predictors of (chemo)radiotherapy outcome in patients with nasopharyngeal carcinoma (NPC). Methods: We genotyped five potentially functional single nucleotide polymorphisms (SNPs) of three genes in the BER pathway in 174 NPC patients who were treated with (chemo)radiotherapy. Sequenom MassArray was used for SNPs analysis. The efficacy at the end of radiotherapy and at 3 months after radiotherapy was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST)...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29104864/imaging-therapy-response-of-gastrointestinal-stromal-tumors-gist-with-fdg-pet-ct-and-mri-a-systematic-review
#20
REVIEW
Antonia Dimitrakopoulou-Strauss, Ulrich Ronellenfitsch, Caixia Cheng, Leyun Pan, Christos Sachpekidis, Peter Hohenberger, Thomas Henzler
Purpose: Improvement of the therapeutic approaches in gastrointestinal stromal tumors (GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which allow sufficient assessment of therapeutic response, including differentiation of true progression from pseudoprogression due to myxoid degeneration or intratumoral hemorrhage. In this literature review the impact and limitations of different imaging modalities used in GIST therapy monitoring are discussed. Methods: PubMed and Cochrane library search were performed using appropriate keywords...
2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
keyword
keyword
18088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"